<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03259659</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00095405</org_study_id>
    <nct_id>NCT03259659</nct_id>
  </id_info>
  <brief_title>Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis</brief_title>
  <official_title>Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To prove that patients with ulcerative proctitis and proctosigmoiditis have impaired
           autonomic functions, i.e. increased sympathetic activity and/or reduced vagal tone.

        2. To demonstrate inflammatory cytokine imbalance, i.e., increased pro-inflammatory
           cytokines. Presence of these abnormalities would make patients with ulcerative proctitis
           and proctosigmoiditis good candidates for future sacral nerve stimulation therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>symptoms characteristics in ulcerative colitis patients</measure>
    <time_frame>1 day</time_frame>
    <description>ulcerative colitis disease activity index will be assessed using the Mayo scoring system, which includes stool frequency, rectal bleeding, mucosal appearance at endoscopy and physician rating of disease activity. The patient will get a score from 0 to 20, with higher score indicating more severe disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>autonomic profile characteristics in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>heart rate variability indicating sympathetic and parasympathetic activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Granulocyte-colony stimulating factor (G-CSF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Eotaxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Granulocyte-macrophage colony-stimulating factor (GM-CSF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -1α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Macrophage Inflammatory Proteins (MIP) -1α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -1β</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Epidermal growth factor (EGF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -12p70</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Interferon gamma (IFNγ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -17A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, interleukin (IL) -18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Monocyte Chemoattractant Protein-1 (MCP-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Interferon - induced protein 10 (IP-10),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, growth regulated oncogene (GRO)/Keratinocyte chemoattractant KC/cytokine-induced neutrophil chemoattractant (CINC)-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Vascular endothelial growth factor (VEGF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Fractalkine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Lipopolysaccharide-induced CXC chemokine (LIX)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Macrophage Inflammatory Proteins (MIP) -2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, Tumor necrosis factor (TNF) α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory cytokine profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>blood sample, RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microbiota profile in ulcerative colitis patients and healthy controls</measure>
    <time_frame>1 day</time_frame>
    <description>fecal sample microbiota analysis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>irritable bowel disease patient</arm_group_label>
    <description>Patients with ulcerative proctitis and proctosigmoiditis who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <description>Healthy participates who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index</intervention_name>
    <description>In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.</description>
    <arm_group_label>irritable bowel disease patient</arm_group_label>
    <arm_group_label>healthy control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample for inflammatory cytokines, fecal sample for microbiota
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        irritable bowel disease patients and healthy controls.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No any systemic diseases;

          -  no proctitis or proctosigmoiditis;

          -  no history of gastrointestinal surgery;

          -  no symptoms of diarrhea or fecal urgency during the past 2 weeks;

          -  not taking any medications except contraceptives during the past 2 weeks;

          -  age 18-65.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiande Chen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiande Chen, PhD</last_name>
    <phone>832-640-8111</phone>
    <email>jchen184@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jieyun Yin</last_name>
    <phone>4105506854</phone>
    <email>jyin12@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiande Chen</last_name>
      <phone>832-640-8111</phone>
      <email>jchen184@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jieyun Yin</last_name>
      <phone>4105506854</phone>
      <phone_ext>Chen</phone_ext>
      <email>jyin12@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Proctitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

